NANO Nanobiotix SA

NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA

NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA
EN
13/10/2020

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX Announces Regulatory Harmonization and New Composition of M...

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other major marketsMedicinal product classification supports unified global regulatory classification, facilitating future global strategies and filingsNew composition of matter patent for JNJ-1900 (NBTXR3) filed by Nanobitotix PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -...

2h / 37m 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX annonce une harmonisation réglementaire et le dépôt d’une d...

NANOBIOTIX annonce une harmonisation réglementaire et le dépôt d’une demande d’un nouveau brevet de composition de matière pour JNJ-1900 (NBTXR3) Les autorités de santé des principaux pays européens ont accepté la reclassification de JNJ-1900 (NBTXR3) en tant que médicament, au lieu de dispositif médical, alignant ainsi son statut réglementaire sur celui en vigueur aux États-Unis et dans d'autres marchés majeurs.Cette classification en tant que médicament permet une harmonisation réglementaire mondiale, facilitant les futures stratégies et dépôts réglementaires internationaux.Un nouveau bre...

2h / 37m 1 EN
Free Trial
NANO NANOBIOTIX SA

Nanobiotix: 1 director

A director at Nanobiotix bought 11,000 shares at 5.622USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

06/18/25 June 18, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, June 10, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2May 31, 202547,426,85149,529,24449,507,126   About NANOBIOTIX...

June 10, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 10 juin 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable231 mai 202547 426 85149 529 24449 507 126 À prop...

June 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch